Traditional and new aspects in the treatment of BPH (on Materials of the 11th South Eastern European Meeting (SEEM) of European Association of Urology)
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. Исследование Проспект 2 (ПРОСтамол: ПЕрспективы Комбинированной Терапии) при ДГПЖ // Здоровье мужчины. – 2012. – No 1. – С. 56–60.
Berges R.R., Pientka L., Hufner K. et al. 2001. Male lower urinary tract symptoms and related health care seeking in Germany// Eur. Urology. 39: 682.
Bostanci Y., Kazzazi A., Momtahen S., Laze J., Djavan В. 2013. Correlation between benign prostatic hyperplasia and inflammation // BENIGN PROSTATIC HYPERPLASIA. 23 .(1): 5–10.
De Marzo A.M., Platz E.A., Sutcliffe S. et al. Inflammation in prostate carcino genesis. 2007.// Nat Rev.7: 256–269.
Di Silverio F., Bosman C., Salvatori M. et al. 2005. Combination therapy with rofecox ib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur. Urol. 47: 72–79.
Elkahwaji J.E., Zhong W., Bushman W. 2007. Chronic bacterial infection and inflam mation incite reactive hyperplasia in a mouse model of chronic prostatitis // Prostate.67:14–21.
Ficarra V, Rossanese M, Zazzara M et. al. 2014. The role of inflammation in lower uri nary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy//Curr Urol Rep.15 (12): 463.
Forray C., Bard J.A., Wetzel J.M. et al. 1994. The б1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human б1с sub type. Mol. Pharmacol. 45 (4): 703–708.
Lowe F., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia 2002.// Curr. Opin. Urol. 12: 15.
Naber K., Weidner W. Chronic prostati tis: an infectious disease? 2000. // J Antimicrob. Chemother. 46:157–161.
Palapattu G.S., Sutcliffe S., Bastain P.J., Platz E.A. 2004. Prostate car cinogenesis and inflammation: emerging insights //Carcinogenesis. 26: 1170–1181.
Sugar L.M. Inflammation and prostate cancer. 2006. //Can J Urol. 13(1): 46–47.
Zhou T, Yang Y, Zhang H et al. 2014. Serenoa Repens Induces Growth Arrest, Apoptosis and Inactivation of STAT3 Signaling in Human Glioma Cells // Technol Cancer Res Treat. 16: 12–16.
Горпинченко І.І., Гурженко Ю.М., Спиридоненко В.В. Патогенетичні аспекти застосування екстракту s.repens і тамсулозину з метою зменшення ускладнень після трансуретральної резекції простати з приводу доброякісної гіперплазії передміхурової залози // Новости медиц. и фармац. – 2015. –No 1 (525). – С. 6–8.
